Skip to main content
OpenTrials
Completed

NCT Number: NCT02332967

Safety and Efficacy of Addition of Structured Lipids in Starter Formulas

The primary objective of this trial is to demonstrate that infants receiving an infant formula in which 40 or 50% of the palmitic acid is in the sn-2 position have, during the first 4 months of life, stools that are softer than those of infants receiving a control formula.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 week–4 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Human milk is considered as the golden standard for infant formula. In human milk and infant formula lipids provide about 55% of energy for the infant and represent as such a major nutrient for the baby. The vast majority of the lipids in human milk is composed of triacylglycerols (98% of total lipids) and the remainder percent are phospholipids. Triglycerides are composed of the glycerol backbone to which three fatty acids are bound. In human milk, palmitate (16:0) is the major long chain saturated fatty acid representing 22% to 26% of total fatty acids, esterified to approximately 70% in sn-2 position on the glycerol backbone. Unsaturated fatty acids such as oleic acid (18:1) and linoleic acid (18:2n-6) are preferentially esterified at the 1 and 3 position. In infant formulas the major source of palmitic acid is palm oil or palm olein where palmitate is, however, preferentially in the external 1,3 positions, and mono- and polyunsaturated fatty acids are usually esterified at the 2-position of the triacylgycerol.

The aim of this study is to assess the safety and efficacy of infant formula containing 40% and 50%, respectively, of palmitic acid in sn-2 position.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy newborn infants
  • full term infant (37 - 42 weeks gestation)
  • birth weight between 2.5 and 4.5 kg
  • singleton birth
  • the infant's mother has elected to exclusively formula feed her baby, from enrollment to 4 months of age
  • having obtained his7her legal representative's informed consent

Exclusion criteria

  • congenital illness or malformation that may affect normal growth
  • significant pre-natal and/or post-natal disease
  • hospitalization in the first 14 days of life after the child has left the maternity ward
  • receiving antibiotic treatment at time of enrolment
  • newborn whose parents/caregivers cannot be expected to comply with treatment
  • newborn currently participating in another interventional clinical trial.

Treatment and study plan

Whey predominant starter formula

Other

Milk powder product given to babies between 1 week and 4 months

Whey predominant starter formula + 40% palmitic acid

Other

Milk powder product containing 40% of palmitic acid

Whey predominant starter formula + 50% palmitic acid

Other

Milk powder product containing 50% of palmitic acid

Primary outcomes

  1. Stool consistency

    Time frame: 4 months

    To demonstrate that the infants receiving an infant formula with 40% or 50% of palmitic acid during the first 4 months of life have softer stools than the ones receiving the control formula.

  2. Baby weight gain

    Time frame: 4 months

    To demonstrate that the weight gain in babies receiving the experimental formula is the same as with the control formula

Secondary outcomes

  1. Baby length and head circumference

    Time frame: 4 months

    To assess whether the groups have comparable changes in length, and head circumference

  2. Digestive tolerance using a questionnaire filled in by the mothers

    Time frame: 4 months

    To assess the infants' digestive tolerance of the starter formula

  3. Gut microbiota using microbiology method

    Time frame: 4 months

    To compare gut microbiota between the groups

  4. Fat quantity in the stools

    Time frame: 4 months

    To assess fat absorption

  5. Baby body composition (DEXA)

    Time frame: 4 months

    To compare body composition

  6. Food intake by the baby

    Time frame: 4 months

    To compare volume intake between the groups

  7. Rate of spitting up

    Time frame: 4 months

    To compare spitting up between the groups

  8. Number of adverse events

    Time frame: 4 months

    To evaluate the frequency of episodes of morbidity (adverse events)

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Jan 7, 2015
Registry last updated
Jan 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.